Apogee Therapeutics FY2025 net loss $255.8M; cash $902.9M; zumilokibart milestones

Apogee Therapeutics, Inc.

Net loss $255.8M (FY2024: $182.1M); R&D expense $214.7M (FY2024: $167.9M).
Cash, equivalents and marketable securities $902.9M; runway into 2H 2028.
APEX Phase 2 Part A 52-week AD data expected March 2026; Part B 16-week data Q2 2026.
Phase 3 AD initiation planned 2H 2026; asthma and EoE trial details later in 2026.
Phase 1b head-to-head APG279 vs DUPIXENT in AD interim data anticipated 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.